No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
Our global team of cancer experts are on hand to provide support and advice to both patients and fellow RGCC clinicians. It’s very simple:
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.Get in touch